Tech Company Financing Transactions
Auspex Pharmaceuticals Funding Round
Auspex Pharmaceuticals, based in La Jolla, received $13.9 million from Thomas, McNerny & Partners and Presidio Partners.
Transaction Overview
Company Name
Announced On
5/6/2008
Transaction Type
Venture Equity
Amount
$13,875,000
Round
Series B
Investors
Thomas, McNerny & Partners (Lead Investor) (Pratik Shah)
Presidio Partners (David Collier)
Proceeds Purpose
Company CEO Ajit Gill said, "This is an exciting time in the company's evolution as it advances multiple compounds toward the clinic, and I am very pleased to join the Auspex team. I believe the company's technology and business strategy have the potential not only to produce best-in-class drugs, but to do so while lowering time, risk and cost of drug development."
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
3366 North Torrey Pines Ct. 225
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Auspex Pharmaceuticals is a developer of next-generation medicines with improved safety and performance and a pioneer in the targeted application of deuterium chemistry to clinically validated drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Pratik Shah
Chief Financial Officer
John Schmid
Chief Medical Officer
David Stamler
Chief Operating Officer
Bharatt Chowrira
Chief Operating Officer
Andreas Sommer
Browse more venture capital transactions:
Prev: 5/6/2008: Mascoma venture capital transaction
Next: 5/6/2008: Deem venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs